메뉴 건너뛰기




Volumn 13, Issue 3, 2012, Pages 395-406

Enhancing intracellular taxane delivery: Current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer

Author keywords

Albumin bound paclitaxel; Metastatic breast cancer; Nab paclitaxel; Nanotechnology

Indexed keywords

ALBUMIN; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CREMOPHOR; DOCETAXEL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; NANOPARTICLE; OSTEONECTIN; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

EID: 84856285214     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.651127     Document Type: Article
Times cited : (74)

References (65)
  • 2
    • 79958043675 scopus 로고    scopus 로고
    • Bethesda, MD: National Cancer Institute. Based on November 2010 SEER data submission, posted to the SEER website,. Available from: [Last accessed 5 October 2011]
    • Howlader N, Noone AM, Krapcho M, et al. editors. SEER Cancer Statistics Review, 1975 - 2008, Bethesda, MD: National Cancer Institute. Based on November 2010 SEER data submission, posted to the SEER website, 2011. Available from: http://seer.cancer.gov/csr/1975-2008/ [Last accessed 5 October 2011]
    • (2011) SEER Cancer Statistics Review, 1975 - 2008
    • Howlader, N.1    Noone, A.M.2    Krapcho, M.3
  • 3
    • 68449084678 scopus 로고    scopus 로고
    • Metastatic breast cancer: Therapeutic options according to molecular subtypes and prior adjuvant therapy
    • Guarneri V, Conte P. Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. Oncologist 2009;14:645-56
    • (2009) Oncologist , vol.14 , pp. 645-656
    • Guarneri, V.1    Conte, P.2
  • 4
    • 42949158252 scopus 로고    scopus 로고
    • Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer
    • Piccart-Gebhart MJ, Burzykowski T, Buyse M, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol 2008;26:1980-6
    • (2008) J Clin Oncol , vol.26 , pp. 1980-1986
    • Piccart-Gebhart, M.J.1    Burzykowski, T.2    Buyse, M.3
  • 5
    • 37849035252 scopus 로고    scopus 로고
    • Taxane-based combinations as adjuvant chemotherapy for early breast cancer: A meta-analysis of randomized trials
    • De Laurentiis M, Cancello G, D'Agostino D, et al. Taxane-based combinations as adjuvant chemotherapy for early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 2008;26:44-53
    • (2008) J Clin Oncol , vol.26 , pp. 44-53
    • De Laurentiis, M.1    Cancello, G.2    D'agostino, D.3
  • 8
    • 0041703019 scopus 로고    scopus 로고
    • Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy
    • DOI 10.2165/00003088-200342070-00005
    • Ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 2003;42:665-85 (Pubitemid 36936530)
    • (2003) Clinical Pharmacokinetics , vol.42 , Issue.7 , pp. 665-685
    • Ten Tije, A.J.1    Verweij, J.2    Loos, W.J.3    Sparreboom, A.4
  • 12
    • 0034880214 scopus 로고    scopus 로고
    • Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation
    • DOI 10.1016/S0959-8049(01)00171-X, PII S095980490100171X
    • Gelderblom H, Verweij J, Nooter K, et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001;37:1590-8 (Pubitemid 32778603)
    • (2001) European Journal of Cancer , vol.37 , Issue.13 , pp. 1590-1598
    • Gelderblom, H.1    Verweij, J.2    Nooter, K.3    Sparreboom, A.4
  • 13
    • 0035003021 scopus 로고    scopus 로고
    • Role of formulation vehicles in taxane pharmacology
    • DOI 10.1023/A:1010618632738
    • Van Zuylen L, Verweij J, Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs 2001;19:125-41 (Pubitemid 32423718)
    • (2001) Investigational New Drugs , vol.19 , Issue.2 , pp. 125-141
    • Van Zuylen, L.1    Verweij, J.2    Sparreboom, A.3
  • 14
    • 61749100209 scopus 로고    scopus 로고
    • Docetaxel-related side effects and their management
    • Baker J, Ajani J, Scotte F, et al. Docetaxel-related side effects and their management. Eur J Oncol Nurs 2009;13:49-59
    • (2009) Eur J Oncol Nurs , vol.13 , pp. 49-59
    • Baker, J.1    Ajani, J.2    Scotte, F.3
  • 16
    • 56949084877 scopus 로고    scopus 로고
    • Albumin as a drug carrier: Design of new drugs, drugs conjugates and nanoparticles
    • Kratz F. Albumin as a drug carrier: design of new drugs, drugs conjugates and nanoparticles. J Control Release 2008;132:171-83
    • (2008) J Control Release , vol.132 , pp. 171-183
    • Kratz, F.1
  • 17
    • 0027931859 scopus 로고
    • Albondin-mediated capillary permeability to albumin. Differential role of receptors in endothelial transcytosis and endocytosis of native and modified albumin
    • Schnitzer JE, Oh P. Albondin-mediated capillary permeability to albumin. Differential role of receptors in endothelial transcytosis and endocytosis of native and modified albumin. J Biol Chem 1994;269:6072-82
    • (1994) J Biol Chem , vol.269 , pp. 6072-6082
    • Schnitzer, J.E.1    Oh, P.2
  • 18
    • 0030798998 scopus 로고    scopus 로고
    • Gp60 activation mediates albumin transcytosis in endothelial cells by tyrosine kinase-dependent pathway
    • DOI 10.1074/jbc.272.41.25968
    • Tiruppathi C, Song W, Bergenfeldt M, et al. Gp60 activation mediates albumin transcytosis in endothelial cells by tyrosin kinase-dependent pathway. J Biol Chem 1997;272:25968-75 (Pubitemid 27438924)
    • (1997) Journal of Biological Chemistry , vol.272 , Issue.41 , pp. 25968-25975
    • Tiruppathi, C.1    Song, W.2    Bergenfeldt, M.3    Sass, P.4    Malik, A.B.5
  • 19
    • 73149105736 scopus 로고    scopus 로고
    • Nanopartcle albumin-bound (nab)-paclitaxel: Improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer
    • Cortes J, Saura C. Nanopartcle albumin-bound (nab)-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer. Eur J Cancer Suppl 2010;8:1-10
    • (2010) Eur J Cancer Suppl , vol.8 , pp. 1-10
    • Cortes, J.1    Saura, C.2
  • 20
    • 33745458519 scopus 로고    scopus 로고
    • Albumin-bound paclitaxel: A next-generation taxane
    • DOI 10.1517/14656566.7.8.1041
    • Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 2006;7:1041-53 (Pubitemid 43949942)
    • (2006) Expert Opinion on Pharmacotherapy , vol.7 , Issue.8 , pp. 1041-1053
    • Gradishar, W.J.1
  • 21
    • 84856290912 scopus 로고    scopus 로고
    • Available from: [Last accessed 1 October 2011]
    • ABRAXANE Healthcare Professional Prescribing Information. 2010. Available from: http://www.abraxane.com/professional/PDF/Abraxane-Healthcare- Professional-Prescribing-Information.pdf [Last accessed 1 October 2011]
    • (2010)
  • 22
    • 84856251695 scopus 로고    scopus 로고
    • Available from: [Last accessed 1 October 2011]
    • Abraxane: EPAR - Product Information. 2011. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000778/WC500020435.pdf [Last accessed 1 October 2011]
    • (2011)
  • 24
    • 11844254414 scopus 로고    scopus 로고
    • Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
    • DOI 10.1126/science.1104819
    • Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62 (Pubitemid 40093472)
    • (2005) Science , vol.307 , Issue.5706 , pp. 58-62
    • Jain, R.K.1
  • 25
    • 33745065712 scopus 로고    scopus 로고
    • SPARC expression in breast tumors may correlate to increased tumor distribution of nanoparticle albumin-bound paclitaxel (ABI-007) vs taxol
    • abstract 5584
    • Trieu V, Frankel T, Labao E, et al. SPARC expression in breast tumors may correlate to increased tumor distribution of nanoparticle albumin-bound paclitaxel (ABI-007) vs taxol. Proc Am Assoc Cancer Res 2005;46:abstract 5584
    • (2005) Proc Am Assoc Cancer Res , vol.46
    • Trieu, V.1    Frankel, T.2    Labao, E.3
  • 26
    • 44449153969 scopus 로고    scopus 로고
    • Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy
    • Volk LD, Flister MJ, Bivens CM, et al. Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy. Neoplasia 2008;10:613-18
    • (2008) Neoplasia , vol.10 , pp. 613-618
    • Volk, L.D.1    Flister, M.J.2    Bivens, C.M.3
  • 29
    • 20344370984 scopus 로고    scopus 로고
    • Comparative preclinical and clinical pharmacokinetics of a Cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol)
    • DOI 10.1158/1078-0432.CCR-04-2291
    • Sparreboom A, Scripture CD, Trieu V, et al. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albuminbound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 2005;11:4136-43 (Pubitemid 40791578)
    • (2005) Clinical Cancer Research , vol.11 , Issue.11 , pp. 4136-4143
    • Sparreboom, A.1    Scripture, C.D.2    Trieu, V.3    Williams, P.J.4    De, T.5    Yang, A.6    Beals, B.7    Figg, W.D.8    Hawkins, M.9    Desai, N.10
  • 30
    • 48249135791 scopus 로고    scopus 로고
    • Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel
    • Gardner ER, Dahut WL, Scripture CD, et al. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 2008;14:4200-5
    • (2008) Clin Cancer Res , vol.14 , pp. 4200-4205
    • Gardner, E.R.1    Dahut, W.L.2    Scripture, C.D.3
  • 31
    • 84856697180 scopus 로고    scopus 로고
    • Phase i and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer
    • Epub ahead of print
    • Ando M, Yonemori K, Katsumata N, et al. Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer. Cancer Chemother Pharmacol 2011. [Epub ahead of print]
    • (2011) Cancer Chemother Pharmacol
    • Ando, M.1    Yonemori, K.2    Katsumata, N.3
  • 32
    • 24944505659 scopus 로고    scopus 로고
    • Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer
    • Ibrahim NK, Samuels B, Page R, et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 2005;23:6019-26
    • (2005) J Clin Oncol , vol.23 , pp. 6019-6026
    • Ibrahim, N.K.1    Samuels, B.2    Page, R.3
  • 33
    • 68949114599 scopus 로고    scopus 로고
    • Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer
    • Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009;27:3611-19
    • (2009) J Clin Oncol , vol.27 , pp. 3611-3619
    • Gradishar, W.J.1    Krasnojon, D.2    Cheporov, S.3
  • 34
    • 84455165693 scopus 로고    scopus 로고
    • Albumin-bound paclitaxel (ab-pac) versus docetaxel for first-line treatment of metastatic breast cancer (MBC): Final overall survival (OS) analysis of a randomized phase II trial
    • abstract 275
    • Gradishar WJ, Krasnojon D, Cheporov S, et al. Albumin-bound paclitaxel (ab-pac) versus docetaxel for first-line treatment of metastatic breast cancer (MBC): Final overall survival (OS) analysis of a randomized phase II trial. J Clin Oncol 2011;29(Suppl 27):abstract 275
    • (2011) J Clin Oncol , vol.29 , Issue.SUPPL. 27
    • Gradishar, W.J.1    Krasnojon, D.2    Cheporov, S.3
  • 35
    • 84856264868 scopus 로고    scopus 로고
    • Nab-paclitaxel versus docetaxel for the first-line treatment of metastatic breast cancer: Overall survival subset analyses of a randomized phase II trial [abstract 5060]
    • Presented at the; 23 - 27 September; Stockholm, Sweden
    • Gradishar WJ, Krasnojon D, Cheporov S, et al. Nab-paclitaxel versus docetaxel for the first-line treatment of metastatic breast cancer: overall survival subset analyses of a randomized phase II trial [abstract 5060]. Presented at the European Multidisciplinary Cancer Congress; 23 - 27 September 2011; Stockholm, Sweden
    • (2011) European Multidisciplinary Cancer Congress
    • Gradishar, W.J.1    Krasnojon, D.2    Cheporov, S.3
  • 36
    • 38049079353 scopus 로고    scopus 로고
    • Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes
    • Blum JL, Savin MA, Edelman G, et al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer 2007;7:850-6
    • (2007) Clin Breast Cancer , vol.7 , pp. 850-856
    • Blum, J.L.1    Savin, M.A.2    Edelman, G.3
  • 37
    • 31444440286 scopus 로고    scopus 로고
    • Superior efficacy of albumin-bound paclitaxel, ABI-007, compared with polyethylated castor oil-based paclitaxel in women with metastatic breast cancer: Results of a phase III trial
    • Gradishar WJ, Tjulandin S, Davidson N, et al. Superior efficacy of albumin-bound paclitaxel, ABI-007, compared with polyethylated castor oil-based paclitaxel in women with metastatic breast cancer: results of a phase III trial. J Clin Oncol 2005;23:1-10
    • (2005) J Clin Oncol , vol.23 , pp. 1-10
    • Gradishar, W.J.1    Tjulandin, S.2    Davidson, N.3
  • 38
    • 36348989864 scopus 로고    scopus 로고
    • Randomized study comparing nab-paclitaxel with solvent-based paclitaxel in Chinese patients (pts) with metastatic breast cancer (MBC)
    • abstract 1038
    • Guan Z, Feng F, Li QL, et al. Randomized study comparing nab-paclitaxel with solvent-based paclitaxel in Chinese patients (pts) with metastatic breast cancer (MBC). J Clin Oncol 2007;25(Suppl 18):abstract 1038
    • (2007) J Clin Oncol , vol.25 , Issue.SUPPL. 18
    • Guan, Z.1    Feng, F.2    Li, Q.L.3
  • 39
    • 80052429731 scopus 로고    scopus 로고
    • Weekly nab-paclitaxel is safe and effective in 65 years old patients with metastatic breast cancer: A post-hoc analysis
    • Aapro M, Tjulandin S, Bhar P, Gradishar W. Weekly nab-paclitaxel is safe and effective in 65 years old patients with metastatic breast cancer: A post-hoc analysis. Breast 2011;20:468-74
    • (2011) Breast , vol.20 , pp. 468-474
    • Aapro, M.1    Tjulandin, S.2    Bhar, P.3    Gradishar, W.4
  • 40
    • 61649107667 scopus 로고    scopus 로고
    • Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nabpaclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531)
    • North Central Cancer Treatment Group
    • Roy V, LaPlant BR, Gross GG, et al. North Central Cancer Treatment Group. Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nabpaclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol 2009;20:449-53
    • (2009) Ann Oncol , vol.20 , pp. 449-453
    • Roy, V.1    Laplant, B.R.2    Gross, G.G.3
  • 41
    • 42549123695 scopus 로고    scopus 로고
    • Phase II trial of nab-paclitaxel (nanoparticle albumin-bound paclitaxel (ABX)) + capecitabine (XEL) in first-line treatment of metastatic breast cancer (MBC)
    • abstract 1053
    • Somer BG, Schwartzberg LS, Arena F, et al. Phase II trial of nab-paclitaxel (nanoparticle albumin-bound paclitaxel (ABX)) + capecitabine (XEL) in first-line treatment of metastatic breast cancer (MBC). J Clin Oncol 2007;25(Suppl 18):abstract 1053
    • (2007) J Clin Oncol , vol.25 , Issue.SUPPL. 18
    • Somer, B.G.1    Schwartzberg, L.S.2    Arena, F.3
  • 42
    • 65749095629 scopus 로고    scopus 로고
    • Phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer
    • abstract 1075
    • Danso MA, Blum JL, Robert NJ, et al. Phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer. J Clin Oncol 2008;26(Suppl 15):abstract 1075
    • (2008) J Clin Oncol , vol.26 , Issue.SUPPL. 15
    • Danso, M.A.1    Blum, J.L.2    Robert, N.J.3
  • 43
    • 77956184020 scopus 로고    scopus 로고
    • Final results of a phase II study of nab-paclitaxel, bevacizumab and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
    • Lobo C, Lopes G, Baez O, et al. Final results of a phase II study of nab-paclitaxel, bevacizumab and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat 2010;123:427-35
    • (2010) Breast Cancer Res Treat , vol.123 , pp. 427-435
    • Lobo, C.1    Lopes, G.2    Baez, O.3
  • 44
    • 76649117610 scopus 로고    scopus 로고
    • Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC)
    • abstract 1006
    • Conlin AK, Hudis CA, Bach A, et al. Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC). J Clin Oncol 2009;27(Suppl 15):abstract 1006
    • (2009) J Clin Oncol , vol.27 , Issue.SUPPL. 15
    • Conlin, A.K.1    Hudis, C.A.2    Bach, A.3
  • 45
    • 77955615612 scopus 로고    scopus 로고
    • Phase II trial of weekly nanoparticle abumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer
    • Conlin AK, Seidman AD, Bach A, et al. Phase II trial of weekly nanoparticle abumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 2010;10:281-7
    • (2010) Clin Breast Cancer , vol.10 , pp. 281-287
    • Conlin, A.K.1    Seidman, A.D.2    Bach, A.3
  • 46
    • 80051769883 scopus 로고    scopus 로고
    • A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer
    • Mirtsching B, Corsgriff T, Harker G, et al. A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer. Clin Breast Cancer 2011;11:121-8
    • (2011) Clin Breast Cancer , vol.11 , pp. 121-128
    • Mirtsching, B.1    Corsgriff, T.2    Harker, G.3
  • 48
    • 24944542869 scopus 로고    scopus 로고
    • Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks
    • Green MC, Buzdar AU, Smith T, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 2005;23:5983-92
    • (2005) J Clin Oncol , vol.23 , pp. 5983-5992
    • Green, M.C.1    Buzdar, A.U.2    Smith, T.3
  • 49
    • 43249115659 scopus 로고    scopus 로고
    • Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of cancer and leukemia group B protocol 9840
    • Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008;26:1642-9
    • (2008) J Clin Oncol , vol.26 , pp. 1642-1649
    • Seidman, A.D.1    Berry, D.2    Cirrincione, C.3
  • 50
    • 84856251698 scopus 로고    scopus 로고
    • Last accessed 5 October
    • ClinicalTrials.gov, Identifier NCT00785291. http://www.clinicaltrial.gov/ ct2/show/NCT00785291 [Last accessed 5 October 2011]
    • (2011)
  • 51
    • 79551628593 scopus 로고    scopus 로고
    • Princeton, NJ: Bristol-Myers Squibb Co. Available from [Last accessed 5 October 2011]
    • IXEMPRA- (ixabepilone) for injection [Prescribing Information]. Princeton, NJ: Bristol-Myers Squibb Co., 2010. Available from: http://packageinserts.bms.com/pi/pi-ixampra.pdf [Last accessed 5 October 2011]
    • (2010) IXEMPRA- (Ixabepilone) for Injection [Prescribing Information]
  • 52
    • 77953014467 scopus 로고    scopus 로고
    • Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer
    • Chan A, Miles D, Pivot X. Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer. Ann Oncol 2010;21:2135-44
    • (2010) Ann Oncol , vol.21 , pp. 2135-2144
    • Chan, A.1    Miles, D.2    Pivot, X.3
  • 53
    • 47949132157 scopus 로고    scopus 로고
    • The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host
    • Podhajcer OL, Benedetti LG, Girotti MR, et al. The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev 2008;27:691-705
    • (2008) Cancer Metastasis Rev , vol.27 , pp. 691-705
    • Podhajcer, O.L.1    Benedetti, L.G.2    Girotti, M.R.3
  • 55
    • 0141482120 scopus 로고    scopus 로고
    • Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients
    • Koukourakis MI, Giatromanolaki A, Brekken RA, et al. Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res 2003;63:5376-80 (Pubitemid 37139854)
    • (2003) Cancer Research , vol.63 , Issue.17 , pp. 5376-5380
    • Koukourakis, M.I.1    Giatromanolaki, A.2    Brekken, R.A.3    Sivridis, E.4    Gatter, K.C.5    Harris, A.L.6    Sage, E.H.7
  • 56
    • 79951917410 scopus 로고    scopus 로고
    • Frequency of potential therapeutic targets identified by immunohistochemistry (IHC) and DNA microarray (DMA) in tumors from patients who have progressed on multiple therapeutic agents
    • abstract 3071
    • Von Hoff DD, Penny R, Shack S, et al. Frequency of potential therapeutic targets identified by immunohistochemistry (IHC) and DNA microarray (DMA) in tumors from patients who have progressed on multiple therapeutic agents. J Clin Oncol 2006;24(Suppl 18):abstract 3071
    • (2006) J Clin Oncol , vol.24 , Issue.SUPPL. 18
    • Von Hoff, D.D.1    Penny, R.2    Shack, S.3
  • 58
    • 77953549226 scopus 로고    scopus 로고
    • SPARC (osteonectin) in breast tumors of different histologic types and its role in the outcome of invasive ductal carcinoma
    • Hsiao YH, Lien HC, Hwa HL, et al. SPARC (osteonectin) in breast tumors of different histologic types and its role in the outcome of invasive ductal carcinoma. Breast J 2010;16:305-8
    • (2010) Breast J , vol.16 , pp. 305-308
    • Hsiao, Y.H.1    Lien, H.C.2    Hwa, H.L.3
  • 59
    • 79151471367 scopus 로고    scopus 로고
    • Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients
    • Nagai MA, Gerhard R, Fregnani JH, et al. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients. Breast Cancer Res Treat 2011;12:1-14
    • (2011) Breast Cancer Res Treat , vol.12 , pp. 1-14
    • Nagai, M.A.1    Gerhard, R.2    Fregnani, J.H.3
  • 60
    • 52649119391 scopus 로고    scopus 로고
    • Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status
    • Desai NP, Trieu V, Hwang LY, et al. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs 2008;19:899-0
    • (2008) Anticancer Drugs , vol.19 , pp. 899-890
    • Desai, N.P.1    Trieu, V.2    Hwang, L.Y.3
  • 61
    • 68649119049 scopus 로고    scopus 로고
    • SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II Study
    • abstract 4525
    • Von Hoff D, Ramanathan E, Borad M, et al. SPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: a phase I/II Study. J Clin Oncol 2009;27(Suppl 15):abstract 4525
    • (2009) J Clin Oncol , vol.27 , Issue.SUPPL. 15
    • Von Hoff, D.1    Ramanathan, E.2    Borad, M.3
  • 62
    • 77952136738 scopus 로고    scopus 로고
    • Correlation of SPARC, ER, PR, and HER2 tumor with progression-free survival from a phase II neoadjuvant trial of gemcitabine, epirubicin, and nabpaclitaxel
    • abstract 618
    • Inhorn RC, Daniel B, Daniel D, et al. Correlation of SPARC, ER, PR, and HER2 tumor with progression-free survival from a phase II neoadjuvant trial of gemcitabine, epirubicin, and nabpaclitaxel. J Clin Oncol 2009;27(Suppl 15):abstract 618
    • (2009) J Clin Oncol , vol.27 , Issue.SUPPL. 15
    • Inhorn, R.C.1    Daniel, B.2    Daniel, D.3
  • 63
    • 84856243348 scopus 로고    scopus 로고
    • SPARC microenvironment signature (SMS) in patients treated with nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab(B) for triple-negative metastatic breast cancer (TNMBC)
    • abstract e21040
    • Blackwell KL, Hamilton EP, Rocha G, et al. SPARC microenvironment signature (SMS) in patients treated with nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab(B) for triple-negative metastatic breast cancer (TNMBC). J Clin Oncol 2010;28(Suppl 15):abstract e21040
    • (2010) J Clin Oncol , vol.28 , Issue.SUPPL. 15
    • Blackwell, K.L.1    Hamilton, E.P.2    Rocha, G.3
  • 64
    • 76949099455 scopus 로고    scopus 로고
    • A phase II neoadjuvant trial of sequential weekly nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer
    • Robidoux A, Buzdar AU, Quinaux E, et al. A phase II neoadjuvant trial of sequential weekly nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer. Clin Breast Cancer 2010;10:81-6
    • (2010) Clin Breast Cancer , vol.10 , pp. 81-86
    • Robidoux, A.1    Buzdar, A.U.2    Quinaux, E.3
  • 65
    • 77950486036 scopus 로고    scopus 로고
    • Results of a multicenter pilot study of weekly nab-paclitaxel, carboplatin with bevacizumab, and trastuzumab as neoadjuvant therapy in HER2+ locally advanced breast cancer with SPARC correlatives
    • abstract 427
    • Yardley DA, Raefsky E, Castillo R, et al. Results of a multicenter pilot study of weekly nab-paclitaxel, carboplatin with bevacizumab, and trastuzumab as neoadjuvant therapy in HER2+ locally advanced breast cancer with SPARC correlatives. J Clin Oncol 2009;27(Suppl 15):abstract 427
    • (2009) J Clin Oncol , vol.27 , Issue.SUPPL. 15
    • Yardley, D.A.1    Raefsky, E.2    Castillo, R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.